

Oral Programme

Sunday 4 September 2016	
12:00-14:30	Registration
14:30-17:00	OPENING PLENARY SESSION: Vaccinology in the 21st Century <i>The Grand Ballroom</i> Chair: Gregory A. Poland, <i>Mayo Clinic, USA</i>
	Session kindly sponsored by: 
14:30-14:40	Opening remarks by Conference Chair Gregory A. Poland , Editor-in-Chief of <i>Vaccine</i> and Alina Helsloot , Publisher of <i>Vaccine</i>
14:45-15:30	[PL.01] Personalized vaccinology: An evolving paradigm in the 21st century Gregory A. Poland, <i>Mayo Clinic, USA</i>
15:30-16:15	[PL.02] Opportunities and challenges for vaccines Rino Rappuoli, <i>GlaxoSmithKline, Italy</i>
16:15-17:00	[PL.03] Age as an obstacle to successful vaccination Myron Levin, <i>University of Colorado, USA</i>
17:00-18:30	Welcome drinks reception <i>The Winter Garden</i> <div style="float: right; width: 40%;"> No Products, No Programs: Why Vaccine Supply Chains Matter <i>The Grand Ballroom</i> An in-depth discussion on the immunization supply chain featuring Raja Rao of the Bill & Melinda Gates Foundation, Heather Deehan of the UNICEF Supply Division, and <i>Vaccine</i> editorial board member Bruce Y. Lee of the Johns Hopkins Bloomberg School of Public Health. </div>
Monday 5 September 2016	
	PLENARY SESSION: Systems Biology & Immunophenotyping <i>The Grand Ballroom</i> Chair: Gregory A. Poland, <i>Mayo Clinic, USA</i>
08:30-09:15	[PL.04] The infant immune system in infection and vaccination Octavio Ramilo, <i>The Ohio State University College of Medicine, USA</i>
09:15-09:35	[PL.05] Systems human immunology: Predicting immune responsiveness John Tsang, <i>National Institutes of Health, USA</i>
09:35-10:00	[PL.06] Broadening the view of immune responses to vaccination and infection Mark Davis, <i>Stanford University, USA</i>
10:00-10:30	Panel discussion
10:30-11:00	Refreshment break <i>The Winter Garden</i>
	BREAKOUT SESSION 1: New technologies (vector/adjuvant/T-Cell immunity) <i>The Grand Ballroom</i> Chairs: Lorne Babiuk, <i>University of Alberta, Canada</i> and Lisa Shollenberger, <i>University of Georgia, USA</i>
	BREAKOUT SESSION 2: Pathogen genomics and antigen discovery <i>The Ruby Room</i> Chairs: Danny Altmann, <i>Imperial College, London</i> and Benjamin Kagina, <i>VACFA, South Africa</i>
11:00-11:30	[B1.1] A novel combination adjuvant platform for human and animal vaccines V. Gerdts ^{*1} , S. Halperin ² , M-N. Kwon ³ , R. Hancock ⁴ , S. van den Hurk ¹ , P. Timms ⁵ , A. Potter ¹ , L. Babiuk ⁶ , ¹ <i>University of Saskatchewan, Canada</i> , ² <i>Dalhousie University, Canada</i> , ³ <i>University of Seoul, Republic of Korea</i> , ⁴ <i>University of British Columbia, Canada</i> , ⁵ <i>University of the Sunshine Coast, Australia</i> , ⁶ <i>University of Alberta, Canada</i>
	[B2.1] Rapid development of vaccines against emerging pathogens Sarah Gilbert, <i>University of Oxford, UK</i>
11:30-11:45	[O01.1] Analyzing internal antigens to be included in a universal adenovector-based influenza A vaccine I. Uddbäck*, J. P Christensen, A. R Thomsen, <i>University of Copenhagen, Denmark</i>
	[O02.1] A combinatorial synthetic peptide vaccine approach protects against superficial and deep tissue infection with hypervirulent group A streptococcus M. Pandey ^{*1} , R. Mortensen ² , A. Calcutt ¹ , E. Langshaw ¹ , V. Ozberk ¹ , J. Powell ¹ , M. Zaman ¹ ,

		M.R. Batzloff ¹ , J. Dietrich ² , M.F. Good ¹ , ¹ Griffith University, Australia, ² Statens Serum Institut, Denmark
11:45-12:00	[O01.2] Antiviral and adjuvant properties of RIG-I agonists J. Hiscott, <i>Istituto Pasteur Italia, Italy</i>	[O02.2] A single amino acid substitution in the envelope protein of dengue virus type 1 suppressed induction of infection-enhancing antibody in a mouse-DNA vaccine model A. Yamanaka ^{*1,2} , E. Konishi ^{1,2} , ¹ Mahidol University, Thailand, ² Osaka University, Japan
12:00-12:15	[O01.3] IL-1β is a potent mucosal adjuvant in adenoviral vector immunizations to enhance heterologous immunity against influenza A D. Lapuente ^{*1} , A. Maaske ¹ , V. Stab ¹ , W. Bayer ² , C. Ehrhardt ³ , M. Tenbusch ¹ , ¹ Ruhr University Bochum, Germany, ² University Duisburg-Essen, Germany, ³ Westfaelische Wilhelms University Muenster, Germany	[O02.3] Enhanced H7N9 influenza vaccine immunogenicity engineered by regulatory T cell epitope deletion in hemagglutinin A. De Groot ^{1,2} , L. Moise ^{1,2} , R. Liu ² , B.C. Lefoley ³ , R. Chan ^{3,4} , M. Ato ⁵ , Y. Takahashi ⁵ , O. Boussadia ^{*1} , T. Ross ³ , W. Martin ¹ , ¹ EpiVax, Inc., USA, ² University of R.I., USA, ³ Center for Vaccines and Immunology, USA, ⁴ University of British Columbia, Canada, ⁵ National Institute of Infectious Diseases, Japan, ⁶ Khon Kaen University, Thailand
12:15-12:30	[O01.4] Chlamydia trachomatis vaccine development: Bridging the gap between murine and non-human primate models T. Kaeser ^{*1,2} , J.A. Pasternak ¹ , M. Delgado-Ortega ¹ , G. Hamonic ¹ , M. Rieder ¹ , K. Lai ¹ , V. Gerdt ¹ , F. Meurens ^{3,4} , ¹ Vaccine and Infectious Disease Organization-InterVac, Canada, ² North Carolina State University, USA, ³ LUNAM Université, France, ⁴ INRA, France	[O02.4] Intranasal vaccination with a live recombinant human rhinovirus and intradermal DNA elicits potent immune responses and contains acute EcoHIV infection in mice K. Tomusange ¹ , D. Wijesundara ¹ , J. Gummow ¹ , Y. Li ¹ , S. Wesselingh ² , A. Suhrbier ³ , B. Grubor-Bauk ¹ , E.J. Gowans ^{*1} , ¹ The University of Adelaide, Australia, ² South Australian Health and Medical Research Institute, Australia, ³ QIMR Berghofer Medical Research Institute, Australia
12:30-12:45	[O01.5] The viral vector vaccine vsv-gp as vaccine platform J. Kimpel ^{*1} , A. Bresk ¹ , R. Tober ¹ , M. Krismer ¹ , S. Schneider ¹ , T. Hofer ¹ , T. Grunwald ² , H.X. Liao ³ , B.F. Haynes ³ , Z. Banki ¹ et al, ¹ Division of Virology, Medical University of Innsbruck, Innsbruck, Austria, ² Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany, ³ Duke University School of Medicine, USA	[O02.5] Unmasking stem-specific broadly neutralizing epitopes by abolishing N-linked glycosylation sites of influenza hemagglutinin proteins for vaccine design W.H. Liu ¹ , Y.J. Huang ¹ , H.H. Lin ^{*1} , J.T. Jan ² , S.C. Wu ¹ , ¹ National Tsing Hua University, Taiwan, ² Academia Sinica, Taiwan
12:45-13:00	[O01.6] eVLP delivery of an optimized form of CMV gB antigen for prophylactic vaccination against congenital CMV M. Kirchmeier, C. Share, T. Ahmed, A. Dress, B. Ontsouka, J. Bozic, A-C. Fluckiger, D.E. Anderson, F. Diaz-Mitoma [*] , <i>VBI Vaccines, USA</i>	[O02.6] Evaluating Burkholderia mallei tonB/hcp1 mutant's vaccine potential against respiratory glanders C.L. Hatcher, A.G. Torres [*] , <i>UTMB Health, USA</i>
13:00-14:30	Lunch <i>The Winter Garden</i>	
13:30-14:30	Workshop: Publish or Perish. How to Become a Successful Author- Organized by the Vaccine Editorial Team- Gregory A. Poland, Elena Kostova, Alina Helsloot and Kerstin Wernike , <i>Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Germany</i>	
	BREAKOUT SESSION 3: Vaccines for the developing world The Grand Ballroom Chairs: Jerome Kim, <i>International Vaccine Institute, Korea</i> and Mariana Baz, <i>Laval University, Canada</i>	BREAKOUT SESSION 4: Biodefense The Ruby Room Chairs: Anthony R. Fooks, <i>AHVLA, UK</i> and Florian Krammer, <i>Icahn School of Medicine at Mount Sinai, USA</i>
	Session kindly sponsored by: 	
14:30-15:00	[B3.1] The pressing need for a group a streptococcus vaccine Jerome Kim, <i>International Vaccine Institute, Korea</i>	[B4.1] Yellow fever 17D vaccine: A very successful live attenuated vaccine but still problems with supply and demand Alan Barrett, <i>University of Texas Medical Branch, USA</i>

15:00-15:15	<p>[O03.1] Factors influencing missed opportunities of routine immunization in a poliomyelitis high-risk province of Pakistan A. Rose¹, M.T. Shah*², S. Sakurada^{2,4}, L. Hashmat³, H. Ueki², P. Kamal¹, ¹<i>Khyber Pakhtunkhwa Provincial Department Of Health Director of EPI Cell, Pakistan</i>, ²<i>Japan International Cooperation Agency Pakistan Project for Strengthening Routine Immunization, Japan</i>, ³<i>Civil Society Human and Institutional Development Programme (CHIP), Pakistan</i>, ⁴<i>Japan National Center for Global Health and Medicine, Japan</i></p>	<p>[O04.1] Development of a live attenuated vaccine against tick-borne encephalitis virus based on control of virus neuropathogenesis and tissue tropism by RNA interference N.L. Teterina*, K.A. Tsetsarkin, O.A. Maximova, H. Kenney, G. Liu, A.G. Pletnev, <i>National Institute of Allergy and Infectious Diseases, NIH, USA</i></p>
15:15-15:30	<p>[O03.2] Multipronged approaches for bioprocessing of bacterially-produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen A. Tekewe, Y. Fan, E. Tan, A.P.J. Middelberg, L.H.L. Lua*, <i>The University of Queensland, Australia</i></p>	<p>[O04.2] Proteomic/serological screens for identification of novel <i>Bacillus anthracis</i> virulence factors and their application in the development of a safe live attenuated anthrax vaccine based on the SterneΔhtra strain T. Chitlaru*, M. Israeli, U. Elia, E. Bar-Haim, S. Rotem, O. Cohen, A. Shafferman, <i>Israel Institute for Biological Research, Israel</i></p>
15:30-15:45	<p>[O03.3] Viral determinants of the bias in the HIV-Env specific antibody response R.C.J. Heß*¹, M. Storcksdieck gen. Bonsmann², V. Stab¹, M. Tenbusch¹, K. Überla³, ¹<i>Ruhr-Universität Bochum, Germany</i>, ²<i>Universitätsklinikum Essen, Germany</i>, ³<i>Universitätsklinikum Erlangen, Germany</i></p>	<p>[O04.3] DNA vaccine candidate against smallpox induce memory immune response in BALB/c mice O. Martinez*, E. Miranda, M. Ramirez, S. Santos, M. Otero, <i>University of Puerto Rico-MSC, Puerto Rico</i></p>
15:45-16:00	<p>[O03.4] First report on occult hepatitis B virus infection in South African healthcare workers T.H. Sondlane*¹, L. Mawela¹, L.L. Razwiedani¹, S.G. Selabe¹, R.L. Lebelo¹, J.N. Rakgole¹, M.J. Mphahlele², C. Dochez³, A. De Schryver³, R.J. Burnett¹, ¹<i>Sefako Makgatho Health Sciences University, South Africa</i>, ²<i>Sefako Makgatho Health Sciences University and Medical Research Council, South Africa</i>, ³<i>University of Antwerp, Belgium</i></p>	<p>[O04.4] From virus discovery to intervention A.D.M.E. Osterhaus, <i>University of Veterinary Medicine, Germany</i></p>
16:00-16:15	<p>[O03.5] Developing recombinant poliovirus vaccines for a polio-free world O. Adeyemi*¹, A. Macadam², S. Knowels², C. Nicol¹, L. De Colibus³, H. Fox², M. Bahar³, M. Uchida⁴, S. Lyons⁴, C. Porta³ et al, ¹<i>University of Leeds, UK</i>, ²<i>The National Institute for Biological Standards and Control, UK</i>, ³<i>University of Oxford, UK</i>, ⁴<i>University of Reading, UK</i>, ⁵<i>The Pirbright Institute, UK</i>, ⁶<i>John Innes Centre, UK</i></p>	<p>[O04.5] Development of live measles vaccine vector for new emerging pathogens F. Tangy*¹, S. Brandler¹, N. Escriou¹, H. Vo¹, M. Mura¹, C. Combredet¹, V. Najburg¹, C. Ruffié¹, K. Ramsauer¹, E. Tauber¹ et al, ¹<i>Institut Pasteur, CNRS, France</i>, ²<i>Themis Bioscience, Austria</i></p>
16:15-16:30	<p>[O03.6] Respiratory syncytial virus prefusion f-type subunit vaccines for different target populations B.J. Haijema*¹, K. Leenhouts¹, M.L. van Roosmalen¹, I. Widjaja^{1,2}, P.J.M. Rottier^{1,2}, C.A.M. de Haan^{1,2}, ¹<i>Mucosis BV, The Netherlands</i>, ²<i>Utrecht University, The Netherlands</i></p>	<p>[O04.6] Cross-Neutralisation of Tick-Borne Flaviviruses Following Tick-Borne Encephalitis Virus Vaccination and/or Infection A.J. McAuley¹, B. Sawatsky², T. Ksiazek¹, T. Avsic-Zupanc³, V. von Messling², A.N. Freiberg¹, D. Beasley¹, D.B. Bente*¹, ¹<i>University of Texas Medical Branch, USA</i>, ²<i>Paul-Ehrlich-Institute, Germany</i>, ³<i>Institute of Microbiology and Immunology, Slovenia</i></p>
16:30-18:30	Poster Session 1 & Drinks reception <i>The Winter Garden</i>	
18:30	Gala Dinner- All ticket holders to meet in the NH Krasnopsky hotel lobby for prompt 18:45 departure	
Tuesday 6 September 2016		
PLENARY SESSION: Maternal immunization <i>The Grand Ballroom</i> Chair: Gregory A. Poland, <i>Mayo Clinic, USA</i>		

08:30-09:15	[PL.07] Maternal Immunization Carol Baker, <i>Baylor College of Medicine, USA</i>		
09:15-09:35	[PL.08] Prospects for prevention of Group B streptococcus disease in young infants by vaccination of pregnant women Shabir Madhi, <i>National Institute for Communicable Diseases, South Africa</i>		
09:35-10:00	[PL.09] Pertussis vaccination during pregnancy: state of the art Elke Leuridan, <i>University of Antwerp, Belgium</i>		
10:00-10:30	Panel discussion		
10:30-11:00	Refreshment break <i>The Winter Garden</i>		
	BREAKOUT SESSION 5: One Health & Emerging viruses <i>The Grand Ballroom</i> Chairs: Rory de Vries, <i>Erasmus MC, the Netherlands</i> and Tobias Käser, <i>North Carolina State University, USA</i>	BREAKOUT SESSION 6: Antibiotic Resistant bacteria/TB <i>The Ruby Room</i> Chairs: Richard Titball, <i>University of Exeter, UK</i> and Surendra Karki, <i>University of New South Wales, Australia</i>	
11:00-11:30	[B5.1] AIDS, Avian flu, SARS, MERS, Ebola, Zika ...what next? Albert Osterhaus, <i>University of Veterinary Medicine Hannover, Germany</i>	[B6.1] The impact of vaccines on antimicrobial resistance Anne Von Gottberg, <i>National Institute for Communicable Diseases, South Africa</i>	
11:30-12:00	[B5.2] Clinical development of a recombinant ebola vaccine in the midst of an unprecedented outbreak Beth-Ann Collier-Griswold, <i>Merck, New Jersey, USA</i>	11:30-11:45	[O06.1] A novel therapeutic vaccine against multi-drug resistant tuberculosis in the monkey model, preclinical study and clinical trial M. Okada* ¹ , K. Tomono ² , T. Nakajima ³ , Y. Kaneda ² , Y. Inoue ¹ , A. Kumanogoh ² , K. Tsuyuguchi ¹ , S. Shoji ⁴ , A. Mikami ⁵ , T. Saito ⁶ et al, ¹ <i>National Hospital Organization Kinki-Chuo Chest Medical Center, Japan</i> , ² <i>Osaka University, Japan</i> , ³ <i>Genomidea Co., Japan</i> , ⁴ <i>NHO Tokyo Hospital, Japan</i> , ⁵ <i>Tokai University, Japan</i> , ⁶ <i>NHO Ibaraki-higashi Hospital, Japan</i>
		11:45-12:00	[O06.2] Preclinical evaluation of a candidate O-polysaccharide glycoconjugate vaccine for protection against <i>Klebsiella pneumoniae</i> N. Hegerle* ¹ , B. Curtis ¹ , R. Laufer ¹ , A. Lees ² , S.M. Tennant ¹ , R. Simon ¹ , ¹ <i>Center for Vaccine Development, USA</i> , ² <i>Fina BioSolutions LLC, USA</i>
12:00-12:15	[O05.1] The changing epidemiology of invasive <i>Haemophilus influenzae</i> disease: emergence and global presence of serotype a strains that may require a new vaccine for control R.S.W. Tsang* ¹ , M. Ulanova ¹ , ¹ <i>National Microbiology Laboratory, Public Health Agency of Canada; Canada</i> , ² <i>Northern Ontario School of Medicine, Lakehead University, Canada</i>	[O06.3] "Systems Serology" – a new frontier for dissecting vaccine-induced humoral immune responses A.W. Chung* ¹ , B. Wines ² , L.L. Lu ^{3,4} , T. Rosebrock ⁴ , D. Lauffenburger ⁵ , S. Fortune ⁴ , G. Alter ³ , M. Hogarth ² , N. Curtis ^{1,6} , S.J. Kent ¹ et al, ¹ <i>Doherty Institute for Infection and Immunity, Australia</i> , ² <i>Burnet Institute, Australia</i> , ³ <i>Ragon Institute of MGH, USA</i> , ⁴ <i>Harvard T.H. Chan School of Public Health, USA</i> , ⁵ <i>Massachusetts Institute of Technology, USA</i> , ⁶ <i>Royal Children's Hospital, Australia</i>	
12:15-12:30	[O05.2] Characterization of newly emerged highly pathogenic avian influenza H5N6 virus of clade 2.3.4.4. M. Richard, <i>Erasmus MC, The Netherlands</i>	[O06.4] A recombinant BCG-LTAK63 strain generates early recruitment of cells and a Th1 immune response increasing protection against tuberculosis C.C. Santos* ^{1,2} , I.P. Nascimento ¹ , D. Rodriguez ¹ ,	

		L.C.C. Leite ^{1,2} , ¹ Instituto Butantan, Brazil, ² Universidade de São Paulo, Brazil
12:30-12:45	[O05.3] Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune Monitoring P. von Hoegen*, T. Knaute, H. Wenschuh, U. Reimer, <i>JPT Peptide Technologies GmbH, Germany</i>	[O06.5] Induction of protective immune responses against group A streptococcus following vaccination with liposomes containing surface-expressed peptide and encapsulated carrier protein M. Zaman* ¹ , V. Ozberk ¹ , J. Reiman ¹ , E.L. Langshaw ¹ , M. Pandey ¹ , M.R. Batzloff ¹ , I. Toth ² , M.F. Good ¹ ¹ Griffith University, Australia, ² The University of Queensland, Australia
12:45-13:00	[O05.4] Lymphocytic choriomeningitis virus vectors expressing gB and pp65 - a new bivalent vaccine that protects against congenital cytomegalovirus infection A. Lilja* ¹ , M. Schleiss ² , U. Berka ¹ , E. Watson ¹ , M. Aistleithner ¹ , B. Kiefmann ¹ , B. Swanson ² , P. Gillis ² , N. Hernandez ² , C. Fernandez-Alarcon ² et al, ¹ Hookipa Biotech AG, Austria, ² University of Minnesota, USA, ³ University of Geneva, Switzerland	[O06.6] Innate-like b cells are activated by the yersinia pestis capsular antigen and are involved in rapid onset of anti-plague immunity Y. Levy*, Y. Vagima, A. Zauberman, M. Aftalion, D. Gur, Y. Flashner, A. Tidhar, E. Mamroud, <i>IIBR, Israel</i>
13:00-14:30	Lunch <i>The Winter Garden</i>	
13:30-15:00	BREAKOUT SESSION 7: BIO-PROCESSING <i>The Grand Ballroom</i> Chairs: Anton Middelberg, <i>University of Queensland, Australia</i> and Antonio Roldao, <i>iBET, Portugal</i>	Speed Review Sessions <i>The Winter Garden</i> Get one-on-one feedback on your manuscript from one of the Editors of <i>Vaccine</i> . Pre-registration recommended.
13:30-14:00	[B7.1] Robust and flexible bioprocessing of molecularly-designed virus-like particle vaccines Linda Lua, <i>University of Queensland, Australia</i>	
14:00-14:15	[O07.1] "Universal" Influenza VLP-based vaccine: What can we learn from producing over thirty different VLPs? A. Roldao ^{1,2} et al, ¹ iBET, Portugal, ² ITQB António Xavier - UNL, Portugal, ³ Pall Life Sciences, UK, ⁴ Pall Life Sciences, USA, ⁵ IMM, Portugal, ⁶ University of Cambridge, UK, ⁷ NIBSC, UK	
14:15-14:30	[O07.2] Purification of enveloped virus-like particles by anion-exchange monoliths and removal of exosomes P. Steppert ¹ , D. Burgstaller ¹ , A. Tover ² , A. Jungbauer* ^{1,3} , ¹ BOKU, Austria, ² Icosagen, Estonia, ³ acib, Austria	
14:30-14:45	[O07.3] Development of HCV vaccine candidates using retroVLPs as manufacturing platform A.F. Rodrigues ^{1,2} , H.R. Soares ^{1,2} , A.I. Almeida ¹ , M. Ferreira-Fernandes ^{1,2} , P.M. Alves ^{1,2} , M.J.T. Carrondo ^{1,3} , A.S.C. Coroadinha* ^{1,2} , ¹ iBET, Apartado 12, Oeiras, Portugal, ² ITQB-UNL, Av. Republica, EAN, Oeiras, Portugal, ³ FCT-UNL, Monte da Caparica, Portugal	
14:45-15:00	[O07.4] Vaccine self-assembling immune matrix is a non-viral delivery platform that improves immunogenicity of recombinant protein vaccines while maintaining safety and stability L.M. Shollenberger*, D.A. Harn <i>University of Georgia, USA</i>	
15:30	Social Networking Afternoon with optional Amsterdam City Tours	
Wednesday 7 September 2016		
PLENARY SESSION: Emerging Vaccines <i>The Grand Ballroom</i>		

	Chair: Gregory A. Poland, <i>Mayo Clinic, USA</i>	
	Session kindly sponsored by:  EXPRES ² ION [®] BIOTECHNOLOGIES	
08:30-09:15	[PL.10] Clinical Development of a tetravalent attenuated Dengue Vaccine. Perspectives of developing a Zika Vaccine <i>Jorge Kalil, Butantan Institute, Brazil</i>	
09:15-10:00	[PL.11] Vaccines for influenza and Ebola viruses <i>Yoshi Kawaoka, University of Wisconsin, USA</i>	
10:00-10:30	Panel discussion	
10:30-11:00	Refreshment break <i>The Winter Garden</i>	
	BREAKOUT SESSION 8: Vaccine safety & hesitancy <i>The Grand Ballroom</i> Chairs: Robert T. Chen, <i>Centers for Disease Control, USA</i> , Steve Jacobsen, <i>Kaiser Permanente, USA</i> and Francesco Nicoli, <i>Centre d'Immunologie et des Maladies Infectieuses de Paris, France</i>	BREAKOUT SESSION 9: HPV <i>The Ruby Room</i> Chairs: F. Xavier Bosch, <i>Catalan Institute of Oncology, Spain</i> , Amy Chung, <i>University of Melbourne, Peter Doherty Institute, Australia</i>
11:00-11:30	[B8.1] A lifecycle perspective to enhancing vaccine safety capacity globally <i>Robert T. Chen, Centers for Disease Control, USA</i>	[B9.1] The combined value of hpv screening and hpv vaccination of women in screening ages <i>F. Xavier Bosch, Catalan Institute of Oncology, Spain</i>
11:30-11:45	[O08.1] Using the clinical study data request initiative to investigate rates of serious adverse events in Latin American infants <i>M. Baay*¹, K. Bollaerts¹, C. Struchiner², T. Verstraeten¹, ¹P95, Epidemiology and Pharmacovigilance Consulting and Services, Belgium, ²Fundação Oswaldo Cruz, Brazil</i>	[O09.1] Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing HPV16 antigens for therapeutic vaccination and cancer immunotherapy <i>A. Lilja*¹, S. Schmidt¹, U. Berka¹, W. Bonilla², Q. Jin³, Y. Ma³, S. Pen³, M. Schwendinger¹, D. Pinschewer², T. Monath¹ et al, ¹Hookipa Biotech AG, Austria, ²University of Basel, Switzerland, ³The Johns Hopkins Medical Institutions, USA</i>
11:45-12:00	[O08.2] Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: the test-negative design case-control study with different control groups <i>E. van Doorn*¹, M. Darvishian², F. Dijkstra³, G. Donker⁴, P. Overduin³, A. Meijer³, E. Hak¹, ¹University of Groningen, The Netherlands, ²University Medical Center Groningen, The Netherlands, ³National Institute for Public Health & Environment, The Netherlands, ⁴NIVEL Primary Care Database, The Netherlands</i>	[O09.2] The DE and FG loops of the HPV major capsid protein are targets for vaccine-induced cross-neutralising antibodies <i>S.L. Bissett*, A. Godi, S. Beddows, Public Health England, UK</i>
12:00-12:15	[O08.3] Impact of an electronic medical record reminder on hepatitis B vaccine initiation rate among adult patients with diabetes mellitus in California <i>R.C. Hechter¹, L. Qian¹, Y. Luo¹, T. Im¹, R. Baxter², K.V. Nunley², L. Aukes², C. Hoge³, G. Krishnarajah⁴, B. Patterson*³ et al, ¹Kaiser Permanente Southern California, USA, ²Kaiser Permanente Northern California, USA, ³GlaxoSmithKline, USA, ⁴CSL Behring, USA</i>	[O09.3] Naturally occurring capsid protein variants of HPV31, HPV33 and HPV45: differential recognition by HPV vaccine antibodies <i>A. Godi*, S.L. Bissett, E. Miller, S. Beddows, Public Health England, UK</i>
12:15-12:30	[O08.4] Seasonal influenza vaccination induces cross-binding antibody responses in healthy subjects and HIV-infected individuals <i>S.B. Egli¹, C. Brumme², V. Greiff⁴, M. Syedbasha¹, M.B. Bigler¹, Z. Brumme^{2,3}, M. Mehling¹, M. Recher¹, A. Egli¹, C.T. Berger*¹, ¹University Hospital Basel, Switzerland, ²British Columbia</i>	[O09.4] Pathogenesis and Immuno-therapy of Hepatitis C virus Infection <i>K.T.K. Kohara*¹, S.S. Sekiguchi², K.K. Kimura³, T.O. Ohtsuki², Y.K. Tokunaga¹, M.K. Kohara¹, ¹Kagoshima University, Japan, ²Tokyo Metropolitan Institute of Medical Science, Japan, ³Komagome Hospital, Japan</i>

	<i>Centre for Excellence in HIV/AIDS, Canada, ³Simon Fraser University, Canada, ⁴ETH Zurich, Switzerland</i>	
12:30-12:45	[O08.5] Is it time for Africa to develop new vaccination policies for HIV-infected individuals? Results from a systematic review B.M. Kagina* ¹ , V. Dirix ² , C.S. Wiysonge ³ , M. Lesosky ¹ , S.A. Madhi ^{4,5} , G.D. Hussey ¹ , ¹ University of Cape Town, South Africa, ² Université Libre de Bruxelles, Belgium, ³ Stellenbosch University, South Africa, ⁴ University of the Witwatersrand, South Africa, ⁵ National Institute for Communicable Diseases, South Africa	[O09.5] Hepatitis b vaccine: chitosan or glucan based delivery systems for efficient oral immunization E. Soares* ¹ , S. Jesus ¹ , O. Borges ¹ , ¹ University of Coimbra, Portugal, ² University of Coimbra, Portugal, ³ University of Coimbra, Portugal
12:45-13:00		[O09.6] #HPV on Pinterest: the anti-vaccine conversation on visual social media J.P.D. Guidry* ¹ , C.A. Orr ¹ , M. Goyal ¹ , K. Carlyle ¹ , M. Messner ¹ , Y. Jin ² , ¹ Virginia Commonwealth University, USA, ² University of Georgia, USA
13:00-14:30	Lunch <i>The Winter Garden</i>	
13:30-14:30	Workshop <i>The Grand Ballroom</i> How to raise funding for your research- Leslie Reperant , <i>Artemis One Health, the Netherlands</i> , Frank Deege , <i>Consultant International Research Grant Applications in Life Sciences & Medicine</i>	
14:30-16:30	Poster Session 2 <i>The Winter Garden</i>	
	BREAKOUT SESSION 10: Vaccine economics and logistics <i>The Grand Ballroom</i> Chairs: Bruce Y. Lee, <i>Johns Hopkins School of Public Health, USA</i> and Auliya Suwantika, <i>University of Padjadjaran, Indonesia</i>	
16:30-17:00	[B10.1] Using HERMES to Assess the Economic Value of Using Drones to Deliver Vaccines Bruce Y. Lee, <i>Johns Hopkins School of Public Health, USA</i>	
17:00-17:15	[O10.1] Polio vaccination during the endgame: Insights from integrated modelling R.J. Duintjer Tebbens*, K.M. Thompson, <i>Kid Risk, Inc., USA</i>	
17:15-17:30	[O10.2] The costs of establishing vaccine production facilities in middle-income countries: an economic evaluation S.L. Munira* ^{1,3} , J.T. Hendriks ² , I. Atmosukarto ¹ , M.H. Friede ⁵ , Y. Chen ¹ , L. Carter ⁴ , A.C.A. Clements ¹ ¹ Australian National University, Australia, ² Institute for Translational Vaccinology (Intravacc), The Netherlands, ³ Universitas Indonesia, Indonesia, ⁴ Australian Nursing and Midwifery Accreditation Council, Australia, ⁵ World Health Organization, Sri Lanka	
17:30	Closing Session	